GE Healthcare

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Jul 14, 2026

Recruiting

Non-Invasive Blood Pressure Accuracy Study for Adult Subject Populations

Jul 9, 2026

Recruiting

Non-Invasive Blood Pressure Accuracy Study for Adult Subject Populations

Jul 9, 2026

Recruiting

Evaluate Functionality and Use of the NMT EasyFit Sensor and NMT EasyFit Cable

Jul 7, 2026

Recruiting

Non-Invasive Blood Pressure Accuracy Study for Neonate and Pediatric Subject Populations

Jul 7, 2026

Withdrawn

Non-Invasive Blood Pressure Accuracy Study for Adult Subject Populations

Earlier

Jun 30, 2026TrialA Prospective, Multicenter Phase 2/3 Study to Assess the Efficacy and Safety of Mangaciclanol in Adult Patients With Known or Highly Suspected Lesions Referred for Contrast-Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) or Body (LUMINA)

Jun 24, 2026TrialData Collection of New Spectral CT Imaging Method

Mar 1, 2026TrialStudy to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

3 more events

Feb 1, 2026TrialStudy to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

Jul 2, 2024TrialA Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers

Apr 24, 2023TrialAltropane Dose for Imaging Patients With Suspected Parkinson's Disease

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Regulatory

Regulatory Timeline

19822 events

FDAJan 1

Hypaque — HYPAQUE

Application NDA011386 (NDA)

FDAJan 1

Hypaque — HYPAQUE

Application NDA009561 (NDA)

19881 event

FDANov 30

Oraltag — OMNIPAQUE 140

Application NDA018956 (NDA)

19931 event

FDAJan 8

Omniscan — OMNISCAN

Application NDA020123 (NDA)

19951 event

FDAOct 24

Oraltag — OMNIPAQUE 350

Application NDA020608 (NDA)

19961 event

FDAMar 22

Visipaque 270 — VISIPAQUE 270

Application NDA020351 (NDA)

19972 events

FDADec 31

Optison — OPTISON

Application NDA020899 (NDA)

FDAAug 29

Visipaque 270 — VISIPAQUE 270

Application NDA020808 (NDA)

20071 event

FDASep 5

Omniscan — OMNISCAN

Application NDA022066 (NDA)

20151 event

FDAMar 26

Oraltag — ORALTAG

Application NDA205383 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)